These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 7692192)

  • 1. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.
    Lanza F; Bi S; Castoldi G; Goldman JM
    Leukemia; 1993 Oct; 7(10):1570-5. PubMed ID: 7692192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
    Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
    Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antileukemic activity of the novel agents norsegoline and dibezine.
    Einat M; Nagler A; Lishner M; Amiel A; Yarkoni S; Rudi A; Gellerman G; Kashman Y; Fabian I
    Clin Cancer Res; 1995 Aug; 1(8):823-9. PubMed ID: 9816051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.
    Martín-Henao GA; Quiroga R; Sureda A; González JR; Moreno V; García J
    Haematologica; 2000 Feb; 85(2):139-46. PubMed ID: 10681720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy.
    Straetmans N; Ma DD; Nevell DF; Arthur C
    Hematopathol Mol Hematol; 1996; 10(4):213-22. PubMed ID: 9042664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
    Després D; Goldschmitt J; Aulitzky WE; Huber C; Peschel C
    Exp Hematol; 1995 Dec; 23(14):1431-8. PubMed ID: 8542928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells.
    Jazwiec B; Mahon FX; Pigneux A; Pigeonnier V; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1509-14. PubMed ID: 8542939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The composition of CD34 subpopulations differs between bone marrow, blood and cord blood.
    Fritsch G; Stimpfl M; Kurz M; Printz D; Buchinger P; Fischmeister G; Hoecker P; Gadner H
    Bone Marrow Transplant; 1996 Feb; 17(2):169-78. PubMed ID: 8640162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavior in vitro of long-term cultured bone marrow or blood cells from chronic myeloid leukemia: adhesion molecules and differentiation antigens as detected by immunocytochemistry.
    Pasternak G; Pasternak L
    Folia Biol (Praha); 1994; 40(6):439-54. PubMed ID: 7589702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrow and mobilised peripheral blood.
    Garin MI; Apperley JF; Melo JV
    Eur J Haematol; 2000 Feb; 64(2):85-92. PubMed ID: 10997328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia.
    Chávez-González A; Rosas-Cabral A; Vela-Ojeda J; González JC; Mayani H
    Leuk Res; 2004 Jun; 28(6):639-47. PubMed ID: 15120942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of enriched CD34+ cells from healthy volunteers and those from patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF).
    Suzuki T; Muroi K; Tomizuka H; Amemiya Y; Miura Y
    Stem Cells; 1995 May; 13(3):273-80. PubMed ID: 7542113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia.
    Jiang YZ; Barrett AJ
    Exp Hematol; 1995 Oct; 23(11):1167-72. PubMed ID: 7556526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype.
    Mesárosová A; Hrivnáková A; Klobusická M; Babusíková O
    Neoplasma; 1995; 42(1):9-14. PubMed ID: 7617076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T lymphoid/myeloid bilineal crisis in chronic myelogenous leukemia.
    Akashi K; Mizuno S; Harada M; Kimura N; Kinjyo M; Shibuya T; Shimoda K; Takeshita M; Okamura S; Matsumoto I
    Exp Hematol; 1993 Jun; 21(6):743-8. PubMed ID: 7684698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and selection of benign stem cells in chronic myeloid leukemia.
    Lemoli RM
    Haematologica; 1993; 78(6):393-400. PubMed ID: 8175034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
    Wu CJ; Biernacki M; Kutok JL; Rogers S; Chen L; Yang XF; Soiffer RJ; Ritz J
    Clin Cancer Res; 2005 Jun; 11(12):4504-11. PubMed ID: 15958636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic phenotype of chronic granulocytic leukaemia progenitor cells in chronic phase and in blastic transformation characterized by means of monoclonal antibodies.
    Robak T
    Arch Immunol Ther Exp (Warsz); 1988; 36(4):471-85. PubMed ID: 3074744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.
    Janssen JJ; Deenik W; Smolders KG; van Kuijk BJ; Pouwels W; Kelder A; Cornelissen JJ; Schuurhuis GJ; Ossenkoppele GJ
    Leukemia; 2012 May; 26(5):977-84. PubMed ID: 22157734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.